Clinical Trial

Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this interventional study is to determine pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) and Efti treatment. This is a prospective single arm interventional trial in patients with early-stage HR+/HER2 -ve breast cancer (Stage I-III) who are eligible for neoadjuvant chemotherapy (NAC). Enrolled patients will be treated with single agent efti for 3 weeks and then start NAC in combination with efti. There are 2 standard NAC usually used and will be determined by treating physician prior to starting on this trial.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-07-28; most recent amendment 2026-06-10.
Trial Details
NCT Number NCT07102940
Lead Sponsor George Washington University
Collaborators: Immutep S.A.S.
Conditions Breast Cancer, HER 2 Negative Breast Cancer, HR Positive/HER-2 Negative Breast Cancer, Stage 1-3
Enrollment 50 participants
Start Date 2026-09-01
Primary Completion 2028-08 (estimated)
Study Completion 2028-08 (estimated)
Updated on ClinicalTrials.gov 2026-06-11